

**Attachment to the current report of Medicalgorithmics S.A. with its registered office in Warsaw (the "Company"; "Issuer")
No. 15/2025 of 17 June 2025.**

A. Information on the members of the Supervisory Board of the new term of office appointed by the General Meeting of the Company on June 17, 2025:

Marzena Piszczek

Date of first appointment to the Supervisory Board of the Company: 12.06.2024

Specializes in the following areas: corporate governance, corporate finance, public finance. Cooperation with practice - major projects: implementation of modern budgeting methods; consolidation and restructuring of the Polish chemical sector, banking sector; implementation of economic standards for the nuclear sector in Poland, supervision over several dozen companies as Director of the Delegation of the Minister of State Treasury. Ms. Marzena Piszczek held a number of positions: president of MARR S.A., vice president of finance, chairwoman of supervisory boards of significant public companies in Poland such as PZU S.A., PKO BP S.A., Grupa Azoty S.A.; member of audit and nomination committees, among others. She has cooperated with ICMA, USAID, and Open Society Institute. She worked as an expert for the Chancellery of the Prime Minister of the Republic of Poland and for the Chancellery of the Senate of the Republic of Poland.

Ms. Marzena Piszczek works at the Cracow University of Economics - as a doctor of economic sciences.

Ms. Marzena Piszczek does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does she participate in any other competitive legal entity as a member of its governing body. She has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

Michał Żółtowski

Date of first appointment to the Supervisory Board of the Company: 17.06.2025

He is a transactional lawyer and has many years of experience in legal support for transactions, including M&A, VC/PE, joint ventures, investment fund services, R&D projects, international technology and intellectual property transfers, due diligence processes, projects involving public aid, and legal services for technology companies. He has served on the Supervisory Boards of numerous entities, including investment funds (e.g., Enerfund ASI SKA) and technology companies (e.g., Holo Surgical S.A., Dystrogen Therapeutics S.A.). He has advised on the creation and operation of VC, CVC, and private investment vehicles. He works in Polish, English, and French.

Mr. Michał Żółtowski is a Doctor of Law (University of Warsaw), Master of Law and Philosophy (Université de Poitiers, University of Warsaw).

Mr. Michał Żółtowski does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

Paweł Lewicki

Date of first appointment to the Supervisory Board of the Company: 16.11.2022 (by resolution of 28.10.2022)

He is a cognitive scientist, an entrepreneur, and investor. He was a professor of cognitive psychology at the University of Tulsa from 1984 through 2009, where he established the Nonconscious Information Processing Laboratory, using multiple research grants from the National Science Foundation and National Institutes of Health.

He was among the first to publish evidence that the advanced expertise acquired by humans from experience, involves multivariate and highly-interactive patterns in data, which are much more complex than what humans are able to consciously articulate or even transfer/communicate. This approach became popular and quickly adopted by the corporate world as so-called “predictive data mining” – making computers derive from Big Data more complex patterns than humans can understand and then use these patterns to make new predictions. Dr. Lewicki started StatSoft, a company that pioneered commercial applications of data mining. StatSoft rapidly became a large developer of data mining solutions for all industries with offices in 30 countries, and over 1 million accounts, where he was a CEO and the main shareholder. StatSoft was sold to Dell in 2014.

As a cognitive scientist, Dr. Lewicki continues to develop artificial intelligence (AI) technologies that make computers smarter. As a businessman, Dr. Lewicki invests in (and helps develop) companies that strive to “make a difference” by using AI to promote the general welfare by accelerating technological progress, especially in the area of medicine, that has been traditionally slower in adopting artificial intelligence.

Mr. Paweł Lewicki does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

Maksymilian Fraszka

Date of first appointment to the Supervisory Board of the Company: 17.06.2025

He is a results-driven finance professional with a strong foundation in the MedTech and biotech sectors. With a proven track record of driving operational efficiency and cost savings through effective forecasting and financial analysis, Maks brings both strategic insight and technical skill to corporate finance teams. Currently serving as a Financial Analyst at ImmunityBio (NASDAQ: IBRX), he supports key G&A functions through budgeting, variance analysis, and monthly reporting.

Mr. Maksymilian Fraszka holds a Bachelor of Science in Finance from the University of Illinois at Chicago, graduating Magna Cum Laude with College Honors.

Mr. Maksymilian Fraszka does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

Michał Wnorowski

Date of first appointment to the Supervisory Board of the Company: 26.06.2018

He has been continuously involved in the capital market since 1995. During his 29-year career, working for financial institutions managing clients' assets and sitting on the supervisory boards of listed and unlisted companies, he has been involved, among other things, in analysing companies' financial statements, building financial models based on financial statements to value companies for investment decisions, working with auditors and valuation consultants from leading audit firms. Since 2002, he has served on the supervisory boards and audit committees of listed companies, with responsibility for overseeing the financial reporting of these companies and supervising the audit of their financial statements by statutory auditors.

Mr. Michał Wnorowski graduated from the Warsaw School of Economics in 1999 with a master's degree.

Mr. Michał Wnorowski does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

B. Information on the members of the Management Board of the Company for the new term of office appointed by the Supervisory Board of the Company on June 17, 2025:

Krzysztof Siemionow

Date of first appointment to the Management Board of the Company: 17.06.2025

Dr. Kris Siemionow, MD, PhD is a board-certified orthopaedic surgeon and an entrepreneur, who founded and co-founded multiple medical companies, that utilize advanced technology to improve clinical outcomes. Dr. Siemionow completed residency at the Cleveland Clinic Foundation in orthopedic surgery and a spine surgery fellowship at Rush University Medical Center. His PhD focused on the effects of inflammation on nerve cell function. Dr. Siemionow is co-founder of Global Spine Outreach a non-for profit organization whose mission is to “save children with severe spinal deformities”.

He co-founded Holo Surgical Inc (acquired), a digital surgery company that developed an artificial intelligence-based surgical guidance system, which is currently in clinical use. He also co-founded Inteneural Networks Inc (acquired), a company that utilizes machine learning to diagnose neurodegenerative disorders. He also co-founded Kardiolytics Inc, a company that utilizes machine learning to perform a virtual coronary stress test.

Dr. Siemionow has authored over 100 peer reviewed articles, abstracts, and book chapters pertaining to surgery and basic science research. He holds 50 patents and patent applications, which have been successfully commercialized.

Dr. Siemionow is currently board member of Dystrogen Therapeutics, Kardiobot, Dystrogen Gene Therapeutics, Kardiolytics, and Biometryks.

Mr. Krzysztof Siemionow does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

Michał Zapora

Date of first appointment to the Management Board of the Company: 17.06.2025

An experienced financial leader with over 15 years of expertise in controlling, financial reporting, and audit. He began his career in consulting firms, including EY, where he spent six years gaining experience in audit and business advisory, participating in projects focused on process optimization, controlling, management reporting, and risk management. He has been with Medicalgorithmics since 2018, gradually developing his role – from Financial Analyst to Financial Controller and Finance Manager. His responsibilities include internal and external reporting, as well as oversight of financial processes and budgeting. Throughout his career, he has also held financial positions in technology startups, where he was responsible for developing financial models, conducting financial analyses, and advancing reporting tools.

He holds a Master's degree in Managerial Economics from the Faculty of Economic Sciences and Management at Nicolaus Copernicus University in Toruń. He also earned a Bachelor's degree in Business Administration from Østfold University College in Norway. He is currently in the final stage of obtaining his statutory auditor certification and is an ACCA student.

Mr. Michal Zapora does not engage in any activity competitive to the Company, does not participate in a competitive company as a partner in a civil law partnership, a partnership, or as a member of a governing body of a capital company, nor does he participate in any other competitive legal entity as a member of its governing body. He has also not been entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.